Astrocyte reactivity influences amyloid-β effects on tau pathology in preclinical Alzheimer's disease.

"Competing interests H.C.K. and G.T.-B. are employees and stockholders of Johnson & Johnson. H.Z. has served on scientific advisory boards and/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZPath, Annexon, Apellis, Artery Therapeutics, AZTherapies, CogRx, Denali, Eisai, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics and Wave; has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure, Biogen and Roche and is a cofounder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). K.B. has served as a consultant, at advisory boards, or at data monitoring committees for Abcam, Axon, Biogen, JOMDD/Shimadzu, Julius Clinical, Lilly, MagQu, Novartis, Prothena, Roche Diagnostics and Siemens Healthineers and is a cofounder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program, all unrelated to the work presented in this paper. S.G. has served as a scientific advisor to Cerveau Therapeutics. E.R.Z. serves on the scientific advisory board of Next Innovative Therapeutics (Nintx). P.R.-N. has served on scientific advisory boards and/or as a consultant for Eisai, Novo Nordisk and Roche. N.J.A. has given lectures in symposia sponsored by Lilly and Quanterix. M.D.I. has received research funding from GE Healthcare and Avid Radiopharmaceuticals. R.C.T. serves as a consultant, advisor and/or on the medical advisory board of Happify Health, Astellas Pharma, Bayer and Hello Therapeutics. GE Healthcare holds a license agreement with the University of Pittsburgh based on the PiB PET technology described in this paper. W.E.K. is a co-inventor of PiB and, as such, has a financial interest in this license agreement. GE Healthcare provided no grant support for this study and had no role in the design or interpretation of results or preparation of this paper. The other authors declare no competing interests."

"We thank all TRIAD, MYHAT and Pittsburgh studies personnel for their effort and participants for their time, data and specimens. We would like to thank the following funding agencies that supported this work: NIH, National Institute of Aging (grants R01AG075336 and R01AG073267 to T.A.P.; RF1AG053504 and R01AG053504 to R.C.T.; RF1AG053504 to P.M.; R01AG052528, P01AG14449 and P01AG025204 to M.D.I.); NIH, National Heart Lung and Blood Institute (grants R01HL105647 and K24HL123565 to R.C.T.); Alzheimer’s Association (grants AARFD-22-974627 to B.B.; AACSF-20-648075 to T.A.P.; AARF-21-850325 to T.K.K.; AARFD-22-923814 to P.C.L.F.; AARGD-21-850670 to E.R.Z.; ADSF-21-831376-C, ADSF-21-831381-C and ADSF-21-831377-C to H.Z.); CAPES (grant 88887.336490/2019-00 to B.B.); CNPq (grant 200691/2021-0 to J.P.F.-S); Fonds de Recherche du Québec—Santé (FRQS; Chercheur Boursier, grant 2020-VICO-279314 to P.R.-N.); CIHR-CCNA Canadian Consortium of Neurodegeneration in Aging (grants MOP-11-51-31; RFN 152985, 159815, 162303 to P.R.-N.); Weston Brain Institute (grants 8400707, 8401154 and 8401103 to P.R.-N.); Colin Adair Charitable Foundation (grant to P.R.-N.); Swedish Research Council, Vetenskapsrådet (grant 2021-03244 to T.K.K.); Wallenberg Scholar (grant 2022-01018 to H.Z.; 2017-00915 and 2022-00732 to K.B.); BrightFocus Foundation (grant A2020812F to T.K.K.); Swedish Alzheimer Foundation (Alzheimerfonden; grant AF-930627 to T.K.K.; AF-930351, AF-939721 and AF-968270 to K.B.); Swedish Brain Foundation (Hjärnfonden; grant FO2020-0240 to T.K.K.); Agneta Prytz-Folkes & Gösta Folkes Foundation (grant 2020-00124 to T.K.K.); European Union’s Horizon Europe research and innovation program (grant 101053962 to H.Z.); Swedish State Support for Clinical Research (grant ALFGBG-71320 to H.Z.); Alzheimer Drug Discovery Foundation (ADDF; grant 201809-2016862 to H.Z.); Bluefield Project, the Olav Thon Foundation, the Erling-Persson Family Foundation, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (grant FO2022-0270 to H.Z.); European Union’s Horizon 2020 research and innovation program under the Marie Skłodowska-Curie (grant 860197 (MIRIADE) to H.Z.); the European Union Joint Program—Neurodegenerative Disease Research (grant JPND2021-00694 to H.Z. and JPND2019-466-236 to K.B.); The UK Dementia Research Institute at UCL (grant UKDRI-1003 to H.Z.); National Academy of Neuropsychology (grant ALZ-NAN-22-928381 to E.R.Z.); Fundação de Amparo a pesquisa do Rio Grande do Sul (FAPERGS; grant 21/2551-0000673-0 to E.R.Z.); Instituto Serrapilheira (grant Serra-1912-31365 to E.R.Z.); Hjärnfonden (grants FO2017-0243 and ALZ2022-0006 to K.B.); The Swedish state under the agreement between the Swedish government and the County Councils, the ALF agreement (grants ALFGBG-715986 and ALFGBG-965240 to K.B.); The Alzheimer’s Association 2021 Zenith Award (grant ZEN-21-848495 to K.B.) and NIH, National Institute of Aging (grants AG052521 and R37 AG023651 supported the MYHAT cohort). Studies composing the Pittsburgh cohort were financed by NIH, National Institute of Aging (grants P30 AG066468, P01AG025204, RF1AG025516, RF1AG052525, R01AG052446 and R01AG052446)."